Please login to the form below

Not currently logged in
Email:
Password:

FDA recommends J&J’s stroke-prevention drug

The FDA has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation

The Food and Drug Administration (FDA) has recommended Xarelto (rivaroxaban) for stroke prevention in patients with the heart condition nonvalvular atrial fibrillation.

Johnson & Johnson, which partnered with Bayer to develop Xarelto, had previously gained approval for its use in reducing the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following knee or hip replacement surgery.

The drug received a positive endorsement from the FDA, despite receiving a critical FDA review two days earlier.

A study into Xarelto as a stroke-prevention drug demonstrated that it was as good as other drugs currently being used. However, when switching from Xarelto to another drug, there is a spike of adverse effects, which has not been fully studied yet.

The ease of taking Xarelto (which is administered as one 20mg pill daily) compares favourably to other treatments, as neither International Normalized Ratio (INR) monitoring nor dietary restrictions are necessary.

13th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dovetail

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics